[ad_1] After an everything rally that pushed major stock indexes near new highs, some investors just want the good stuff. They are looking for quality stocks, broadly defined as shares…
Tag: JNJ
Johnson & Johnson to Acquire Cancer-Treatment Developer Ambrx for $2 Billion
[ad_1] Johnson & Johnson will acquire cancer-treatment developer Ambrx Biopharma in a $2 billion cash deal. The pharmaceutical giant said Monday that the deal to acquire all shares of Ambrx…
Investors Hope the Dogs of the Dow Can Find Their Bite
[ad_1] The Dogs of the Dow weren’t the best in show last year, but the recent rally in beaten-down corners of the stock market is giving hope to fans of…
Johnson & Johnson to Acquire Cancer-Treatment Developer Amrbx for $2B
[ad_1] Johnson & Johnson will acquire cancer-treatment developer Ambrx Biopharma in a $2 billion cash deal. The pharmaceutical giant said Monday that the deal to acquire all shares of Ambrx…
Bond Yields Hit Fresh Multiyear Highs After Hot Retail Sales Data
[ad_1] U.S. government bond yields hit fresh decade-plus highs Tuesday after another hot economic-data release fueled concerns that interest rates could remain elevated for longer. Copyright ©2023 Dow Jones &…
Blockbuster Cancer Treatment Stymied by Supply Chain—for Now
[ad_1] A cell therapy for multiple myeloma promises to be a major blockbuster for J&J and partner Legend, if they can increase manufacturing. [ad_2] Source link